# Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in <i>KMT2A</i>- and <i>NPM1</i>-altered leukemias

*PRI Rank #15 · Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026/rank-15*

| Field | Value |
| --- | --- |
| Rank | #15 |
| 18m citations | 40 |
| Journal | Blood |
| Year | 2024 |
| DOI | 10.1182/blood.2023022480 |
| Corresponding authors | Min Chul Kwon |
| Institution | Janssen R&D, Belgium |

**Ranking page:** [Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026](https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026)

**Paper link:** [10.1182/blood.2023022480](https://doi.org/10.1182/blood.2023022480)

## Topics

JNJ-75276617 · bleximenib · Menin inhibitor · KMT2A-rearranged leukemia · NPM1-mutated AML · protein-protein interaction inhibitor · MEIS1 · FLT3 · Acute myeloid leukemia (AML) · acute lymphoblastic leukemia · gilteritinib · Venetoclax · Azacitidine · MEN1M327I mutation · MEN1T349M mutation · revumenib resistance · Patient-derived xenograft models · chromatin binding inhibition · cocrystal structure · drug synergy

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026. Accessed 2026-07-31.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```